Search

Gallium maltolate

Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

TC-2216

TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders.

4-nitrophenyl-beta-D-galactoside

Bioymifi

Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

CERE-120

CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. … It was under investigation in clinical trials for the treatment of Parkinson's Disease.

SNS-314

SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

Mimopezil

Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease.

Typhoid Vi polysaccharide vaccine

It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. … The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

AT-301

AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine